• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于国际肺癌研究协会(IASLC)残留肿瘤描述符的病理性N2非小细胞肺癌复发动态

Recurrence Dynamics of Pathological N2 Non-Small Cell Lung Cancer Based on IASLC Residual Tumor Descriptor.

作者信息

Kim In Ha, Lee Geun Dong, Choi Sehoon, Kim Hyeong Ryul, Kim Yong-Hee, Kim Dong Kwan, Park Seung-Il, Yun Jae Kwang

机构信息

Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, Ulsan University College of Medicine, Seoul, Korea.

出版信息

Cancer Res Treat. 2025 Jan;57(1):105-115. doi: 10.4143/crt.2024.150. Epub 2024 Jul 23.

DOI:10.4143/crt.2024.150
PMID:39054624
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11729313/
Abstract

PURPOSE

This study investigated the recurrence patterns and timing in patients with pathologic N2 (pN2) non-small cell lung cancer (NSCLC) according to the residual tumor (R) descriptor proposed by the International Association for the Study of Lung Cancer (IASLC).

MATERIALS AND METHODS

From 2004 to 2021, patients with pN2 NSCLC who underwent anatomical resection were analyzed according to the IASLC R criteria using medical records from a single center. Survival analysis was performed using Cox proportional hazards models. Recurrence patterns between complete (R0) and uncertain resections (R[un]) were compared.

RESULTS

In total, 1,373 patients were enrolled in this study: 576 (42.0%) in R0, 286 (20.8%) in R(un), and 511 (37.2%) in R1/R2 according to the IASLC R criteria. The most common reason for R(un) classification was positivity for the highest lymph node (88.8%). In multivariable analysis, the hazard ratios for recurrence in R(un) and R1/R2 compared to R0 were 1.18 (95% confidence interval [CI], 0.96-1.46) and 1.58 (1.31-1.90), respectively. The hazard rate curves displayed similar patterns among groups, peaking at approximately 12 months after surgery. There was a significant difference in distant recurrence patterns between R0 and R(un). Further analysis after stratification with the IASLC N2 descriptor showed significant differences in distant recurrence patterns between R0 and R(un) in patients pN2a1 and pN2a2 disease, but not in those with pN2b disease.

CONCLUSION

The IASLC R criteria has prognostic relevance in patients with pN2 NSCLC. R(un) is a highly heterogeneous group, and the involvement of the highest mediastinal lymph node can affect distant recurrence patterns.

摘要

目的

本研究根据国际肺癌研究协会(IASLC)提出的残留肿瘤(R)描述符,调查了病理N2(pN2)非小细胞肺癌(NSCLC)患者的复发模式和时间。

材料与方法

2004年至2021年期间,对在单一中心接受解剖性切除的pN2 NSCLC患者,根据IASLC的R标准,利用病历进行分析。使用Cox比例风险模型进行生存分析。比较了完全切除(R0)和不确定切除(R[un])之间的复发模式。

结果

本研究共纳入1373例患者:根据IASLC的R标准,576例(42.0%)为R0,286例(20.8%)为R(un),511例(37.2%)为R1/R2。R(un)分类的最常见原因是最高位淋巴结阳性(88.8%)。在多变量分析中,与R0相比,R(un)和R1/R2复发的风险比分别为1.18(95%置信区间[CI],0.96 - 1.46)和1.58(1.31 - 1.90)。风险率曲线在各组间显示出相似的模式,在术后约12个月达到峰值。R0和R(un)之间的远处复发模式存在显著差异。使用IASLC N2描述符分层后的进一步分析显示,pN2a1和pN2a2疾病患者的R0和R(un)之间远处复发模式存在显著差异,但pN2b疾病患者则无差异。

结论

IASLC的R标准对pN2 NSCLC患者具有预后相关性。R(un)是一个高度异质性的组,最高纵隔淋巴结受累可影响远处复发模式。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/97ed/11729313/1322cf1fadcb/crt-2024-150f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/97ed/11729313/53605c180fec/crt-2024-150f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/97ed/11729313/1322cf1fadcb/crt-2024-150f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/97ed/11729313/53605c180fec/crt-2024-150f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/97ed/11729313/1322cf1fadcb/crt-2024-150f2.jpg

相似文献

1
Recurrence Dynamics of Pathological N2 Non-Small Cell Lung Cancer Based on IASLC Residual Tumor Descriptor.基于国际肺癌研究协会(IASLC)残留肿瘤描述符的病理性N2非小细胞肺癌复发动态
Cancer Res Treat. 2025 Jan;57(1):105-115. doi: 10.4143/crt.2024.150. Epub 2024 Jul 23.
2
A Validation Study of the Recommended Change in Residual Tumor Descriptors Proposed by the International Association for the Study of Lung Cancer for Patients With pN2 NSCLC.国际肺癌研究协会建议的 pN2 NSCLC 患者残余肿瘤标志物推荐改变的验证研究。
J Thorac Oncol. 2021 May;16(5):817-826. doi: 10.1016/j.jtho.2021.01.1621. Epub 2021 Feb 16.
3
Validation of the IASLC Residual Tumor Classification in Patients With Stage III-N2 Non-Small Cell Lung Cancer Undergoing Neoadjuvant Chemoradiotherapy Followed By Surgery.IASLC 残留肿瘤分类在接受新辅助放化疗后手术的 III-N2 期非小细胞肺癌患者中的验证。
Ann Surg. 2023 Jun 1;277(6):e1355-e1363. doi: 10.1097/SLA.0000000000005414. Epub 2022 Feb 15.
4
The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer.IASLC 肺癌分期项目:非小细胞肺癌切缘状态分析及残余肿瘤描述符建议。
J Thorac Oncol. 2020 Mar;15(3):344-359. doi: 10.1016/j.jtho.2019.10.019. Epub 2019 Nov 13.
5
Beyond Margin Status: Population-Based Validation of the Proposed International Association for the Study of Lung Cancer Residual Tumor Classification Recategorization.切缘状态之外:国际肺癌研究协会残余肿瘤分类重新分类的基于人群验证。
J Thorac Oncol. 2020 Mar;15(3):371-382. doi: 10.1016/j.jtho.2019.11.009. Epub 2019 Nov 26.
6
[The impact of uncertainty resection on the prognosis of non-small cell lung cancer].[不确定性切除对非小细胞肺癌预后的影响]
Zhonghua Wai Ke Za Zhi. 2024 Aug 1;62(8):764-770. doi: 10.3760/cma.j.cn112139-20240118-00035.
7
Prognostic evaluation of the proposed residual tumor classification in a Chinese non-small cell lung cancer population.在中国非小细胞肺癌人群中对提出的残余肿瘤分类的预后评估。
J Surg Oncol. 2022 May;125(6):1061-1070. doi: 10.1002/jso.26810. Epub 2022 Jan 31.
8
Differences in the Prognostic Impact between Single-Zone and Multi-Zone N2 Node Metastasis in Patients with Station-Based Multiple N2 Non-Small Cell Lung Cancer.基于站的多发N2期非小细胞肺癌患者单区域与多区域N2淋巴结转移的预后影响差异
Cancer Res Treat. 2025 Jan;57(1):95-104. doi: 10.4143/crt.2024.120. Epub 2024 Jul 22.
9
Prognostic Significance of the Proposed Residual Tumor Classification in Patients With NSCLC After Sleeve Lobectomy.肺叶袖状切除术后非小细胞肺癌患者拟用的残余肿瘤分类的预后意义
JTO Clin Res Rep. 2023 Sep 14;4(10):100574. doi: 10.1016/j.jtocrr.2023.100574. eCollection 2023 Oct.
10
Lymph node ratio predicts recurrence and survival after R0 resection for non-small cell lung cancer.淋巴结比率可预测非小细胞肺癌 R0 切除术后的复发和生存。
Ann Thorac Surg. 2013 Oct;96(4):1163-1170. doi: 10.1016/j.athoracsur.2013.04.031. Epub 2013 Aug 30.

本文引用的文献

1
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the Classification of Residual Tumor After Resection for the Forthcoming (Ninth) Edition of the TNM Classification of Lung Cancer.国际肺癌研究协会肺癌分期项目:即将发布的(第九版)肺癌 TNM 分期中关于肺癌切除术后残余肿瘤分类修订的建议。
J Thorac Oncol. 2024 Jul;19(7):1052-1072. doi: 10.1016/j.jtho.2024.03.021. Epub 2024 Apr 1.
2
The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the N Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer.国际肺癌研究协会肺癌分期项目:即将出版的第九版肺癌 TNM 分类中 N 描述符修订建议。
J Thorac Oncol. 2024 May;19(5):766-785. doi: 10.1016/j.jtho.2023.10.012. Epub 2023 Oct 20.
3
Various recurrence dynamics for non-small cell lung cancer depending on pathological stage and histology after surgical resection.手术切除后,非小细胞肺癌根据病理分期和组织学表现呈现出多种复发动态。
Transl Lung Cancer Res. 2022 Jul;11(7):1327-1336. doi: 10.21037/tlcr-21-1028.
4
Validation of the IASLC Residual Tumor Classification in Patients With Stage III-N2 Non-Small Cell Lung Cancer Undergoing Neoadjuvant Chemoradiotherapy Followed By Surgery.IASLC 残留肿瘤分类在接受新辅助放化疗后手术的 III-N2 期非小细胞肺癌患者中的验证。
Ann Surg. 2023 Jun 1;277(6):e1355-e1363. doi: 10.1097/SLA.0000000000005414. Epub 2022 Feb 15.
5
A Validation Study of the Recommended Change in Residual Tumor Descriptors Proposed by the International Association for the Study of Lung Cancer for Patients With pN2 NSCLC.国际肺癌研究协会建议的 pN2 NSCLC 患者残余肿瘤标志物推荐改变的验证研究。
J Thorac Oncol. 2021 May;16(5):817-826. doi: 10.1016/j.jtho.2021.01.1621. Epub 2021 Feb 16.
6
Beyond Margin Status: Population-Based Validation of the Proposed International Association for the Study of Lung Cancer Residual Tumor Classification Recategorization.切缘状态之外:国际肺癌研究协会残余肿瘤分类重新分类的基于人群验证。
J Thorac Oncol. 2020 Mar;15(3):371-382. doi: 10.1016/j.jtho.2019.11.009. Epub 2019 Nov 26.
7
The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer.IASLC 肺癌分期项目:非小细胞肺癌切缘状态分析及残余肿瘤描述符建议。
J Thorac Oncol. 2020 Mar;15(3):344-359. doi: 10.1016/j.jtho.2019.10.019. Epub 2019 Nov 13.
8
Clinical implications of uncertain resection in scenarios of metastasis of the highest or most distant mediastinal lymph node station following surgical treatment of non-small-cell lung cancer.手术治疗非小细胞肺癌后,对于最高或最远处纵隔淋巴结转移部位的不确定切除的临床意义。
Lung Cancer. 2019 Dec;138:1-5. doi: 10.1016/j.lungcan.2019.09.018. Epub 2019 Sep 25.
9
Clinical Significance of 4L Lymph Node Dissection in Left Lung Cancer.左肺癌 4L 淋巴结清扫的临床意义。
J Clin Oncol. 2018 Oct 10;36(29):2935-2942. doi: 10.1200/JCO.2018.78.7101. Epub 2018 Aug 27.
10
Association of Pathologic Nodal Staging Quality With Survival Among Patients With Non-Small Cell Lung Cancer After Resection With Curative Intent.具有治愈意图的非小细胞肺癌切除术后病理淋巴结分期质量与生存的相关性研究。
JAMA Oncol. 2018 Jan 1;4(1):80-87. doi: 10.1001/jamaoncol.2017.2993.